Brief: Innovent Biologics Says Obtained Early Clearance From Federal Trade Commission
March 25 (Reuters) - Innovent Biologics Inc 1801.HK: OBTAINED EARLY CLEARANCE FROM FEDERAL TRADE COMMISSION ALL CONDITIONS PRECEDENT TO EFFECTIVENESS OF STRATEGIC COLLABORATION AGREEMENT BETWEEN LILLY AND CO SATISFIED MEDIA REPORTS HAVE INCORRECTLY INTERPRETATED EFFECTIVENESS OF STRATEGIC COLLABORATION AGREEMENT AS ACQUISITION OF CO CLARIFIES NOT ENGAGED IN PURSUING SUCH TRANSACTION Further company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis